Asthma: diagnosis, monitoring and chronic asthma management
In development [GID-NG10186] Expected publication date: 30 October 2024
Search results
318 results
-
-
Mental health guidelines
This webpage covers all NICE's guidelines on mental health. The table presents the guidelines alphabetically. Updates planned or in progress and areas
-
Cardiometabolic disease prevention and treatment guidelines
This webpage covers all NICE's guidelines on cardiometabolic disease prevention and treatment The table presents the guidelines alphabetically within...
-
Breast cancer guidelines
This webpage covers NICE guidelines on breast cancer. The table below presents the guidelines alphabetically with links to the surveillance report...
-
Suspected sepsis: recognition, diagnosis and early management
NICE is updating its guideline on suspected sepsis: recognition, diagnosis and early management (NG51) . Updates in progress For people covered by...
-
Women's and reproductive health guidelines
This webpage covers all NICE's guidelines on women's and reproductive health. The table presents the guidelines alphabetically. Updates planned or in...
-
Kidney Cancer
In development [GID-NG10398] Expected publication date: TBC
-
Bipolar disorder: assessment and management (extraordinary review)
In development [GID-NG10380] Expected publication date: TBC
-
Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)
In development [GID-NG10415] Expected publication date: TBC
-
Suspected sepsis: recognition, diagnosis and early management
In development [GID-NG10412] Expected publication date: 13 August 2025
-
Menopause: diagnosis and management
In development [GID-NG10241] Expected publication date: TBC
-
Overweight and obesity management
In development [GID-NG10182] Expected publication date: TBC
-
Pneumonia: diagnosis and management (update)
In development [GID-NG10357] Expected publication date: TBC
-
Fertility problems: assessment and treatment
In development [GID-NG10263] Expected publication date: 29 May 2025
-
Urinary Tract Infection (recurrent): antimicrobial prescribing
In development [GID-NG10422] Expected publication date: 13 November 2024
-
Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure
In development [GID-NG10405] Expected publication date: TBC
-
Diabetic retinopathy
In development [GID-NG10256] Expected publication date: TBC
-
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)
In development [GID-NG10216] Expected publication date: TBC
-
Harmful gambling: identification, assessment and management
In development [GID-NG10210] Expected publication date: 30 May 2024
-
Adrenal insufficiency: identification and management
In development [GID-NG10237] Expected publication date: 28 August 2024
-
Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)
In development [GID-NG10419] Expected publication date: 31 March 2025
-
Endometriosis: diagnosis and management - diagnosing endometriosis
In development [GID-NG10392] Expected publication date: 10 July 2024
-
Type 2 diabetes in adults: management (medicines update)
In development [GID-NG10336] Expected publication date: 04 December 2024
-
Rehabilitation for chronic neurological disorders including acquired brain injury
In development [GID-NG10181] Expected publication date: 21 May 2025
-
Falls: assessment and prevention in older people and people 50 and over at higher risk (update)
In development [GID-NG10228] Expected publication date: 26 March 2025
-
Maternal and child nutrition
In development [GID-NG10191] Expected publication date: 13 November 2024
-
Acute kidney injury: prevention, detection and management - Assessing risk factors for acute kidney injury in adults having iodine-based contrast media
In development [GID-NG10410] Expected publication date: 16 October 2024
-
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma [Review of TA540] [ID5084]
In development [GID-TA11317] Expected publication date: 01 May 2024
-
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [ID6261]
In development [GID-TA11297] Expected publication date: 08 May 2024
-
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]
In development [GID-TA10813] Expected publication date: 15 May 2024
-
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]
In development [GID-TA10646] Expected publication date: 15 May 2024
-
Atogepant for preventing migraine [ID5090]
In development [GID-TA10992] Expected publication date: 15 May 2024
-
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (MA review of TA554) [ID6290]
In development [GID-TA11381] Expected publication date: 15 May 2024
-
Managing common infections - antimicrobial prescribing guidelines
In development [GID-NG10050] Expected publication date: TBC
-
Epilepsies in children, young people and adults (extraordinary review)
In development [GID-NG10378] Expected publication date: TBC
-
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
In development [GID-NG10404] Expected publication date: TBC
-
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome [ID3947]
In development [GID-TA10834] Expected publication date: 22 May 2024
-
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]
In development [GID-TA10653] Expected publication date: 22 May 2024
-
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
In development [GID-TA10446] Expected publication date: TBC
-
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
In development [GID-TA10326] Expected publication date: TBC
-
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
In development [GID-TA10223] Expected publication date: TBC
-
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]
In development [GID-TA10248] Expected publication date: TBC
-
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
In development [GID-TA10542] Expected publication date: TBC
-
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]
In development [GID-TA10607] Expected publication date: TBC
-
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
In development [GID-TA10573] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
In development [GID-TA10623] Expected publication date: TBC
-
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
In development [GID-TA10250] Expected publication date: TBC
-
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
In development [GID-TA10664] Expected publication date: TBC
-
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340
In development [GID-TA10313] Expected publication date: TBC
-
NY-ESO-1 T-cells for treating synovial sarcoma ID1286
In development [GID-TA10205] Expected publication date: TBC